Information Provided By: 
Fly News Breaks for January 31, 2017
DRNA
Jan 31, 2017 | 07:53 EDT
Leerink analyst Paul Matteis assumed coverage of Dicerna with a Market Perform rating and $4 price target. While the analyst believes the company's pipeline has long-term clinical potential, nearer term he is somewhat concerned by its limited cash runway and lack of news flow.
News For DRNA From the Last 2 Days
There are no results for your query DRNA
